PepGen Inc. PEPG
2.39 USD -0.08 (-3.24%)
At closeNov 9, 2026, 7:13 PM EST
2.40 +0.01 +0.42%
After hours · Nov 9, 7:13 PM ET
2.28 Day range 2.52
1.31 52-week range 7.80
- YTD
- -63.29%
- 1 year
- -48.27%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
benzinga.com HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $20 Price Target HC Wainwright & Co. analyst Ananda Ghosh reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $20 price target.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out…
benzinga.com PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per…
benzinga.com PepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into…
benzinga.com Craig-Hallum Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $11 Craig-Hallum analyst Adam Vogel initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $11.
benzinga.com PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15 PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and…- benzinga.com PepGen Files For $400M Shelf Registration And $100M At-The-Market Stock Offering https://www.sec.gov/Archives/edgar/data/1835597/000119312526228960/d132482ds3.htm
benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $4 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $5 to $4.
benzinga.com PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 71.74 percent increase over losses of $(0.92) per…
benzinga.com Top 3 Health Care Stocks Which Could Blast Off This Quarter Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)
benzinga.com Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on top names. For a complete view of all rating changes, see analyst ratings page.- benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $9 to $5.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.2%, while utilities fall 0.7%. FactSet reports upbeat Q2 results and raises outlook.- benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $9 to $5.
benzinga.com Dow Jumps 400 Points; TD Synnex Posts Upbeat Earnings US stocks higher, Dow up 0.90%, Nasdaq up 1.61%. Communication services gained 1.8%, utilities fell 0.6%. TD Synnex beats earnings estimates.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Is PepGen Stock Sinking Tuesday? PepGen stock drops after Phase 2 low-dose data show limited splicing correction; higher-dose cohorts and FDA hold remain key focus areas.
benzinga.com Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its second SpaceShip is expected to enter service soon, causing a 6% jump in pre-market trading. Other…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com PepGen Announces Clinical Data From The 5 Mg/Kg Multiple Ascending Dose Cohort Of The Ongoing Phase 2 FREEDOM2-DM1 Trial In Patients With Myotonic Dystrophy Type 1; PGN-EDOM1 Was Generally Well-Tolerated With All Adverse Events Mild Or Moderate And No Serious Adverse Events Reported PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and…
benzinga.com Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down.
benzinga.com Grocery Outlet Posts Downbeat Q4 Earnings, Joins SES AI, PepGen And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures mixed, Grocery Outlet Holding Corp shares fall 26.3% in pre-market trading after reporting lower earnings and sales. Other stocks declining in pre-market.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Veeva Systems Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Shares of Veeva Systems Inc (NYSE: VEEV) gained 11.3% in pre-market trading on upbeat Q4 results and FY27 guidance above estimates.
benzinga.com FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial PepGen (PEPG) shifts focus to DM1 but faces a fresh FDA roadblock. Clinical data, analyst ratings, and technical support levels inside.- benzinga.com PepGen Inc. FREEDOM2 Trial Placed On Partial FDA Hold Related To Preclinical Pharmacology And Toxicology; Cleared To Proceed In South Korea, Australia, And New Zealand And Dosing Of The 10 mg/kg Cohort Continues In The UK And Canada; Data Expected In 2026 - U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology -- Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New…
- benzinga.com PepGen Q4 EPS $(0.27) Beats $(0.36) Estimate PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.36) by 25.41 percent. This is a 60.29 percent increase over losses of $(0.68) per…
- benzinga.com Oppenheimer Initiates Coverage On PepGen with Outperform Rating, Announces Price Target of $15 Oppenheimer analyst Kostas Biliouris initiates coverage on PepGen (NASDAQ:PEPG) with a Outperform rating and announces Price Target of $15.
- benzinga.com Guggenheim Maintains Buy on PepGen, Raises Price Target to $7 Guggenheim analyst Debjit Chattopadhyay maintains PepGen (NASDAQ:PEPG) with a Buy and raises the price target from $6 to $7.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Meihua International Medical Technologies, Fly-E Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com HC Wainwright & Co. Maintains Buy on PepGen, Raises Price Target to $20 HC Wainwright & Co. analyst Ananda Ghosh maintains PepGen (NASDAQ:PEPG) with a Buy and raises the price target from $18 to $20.
- benzinga.com HC Wainwright & Co. Maintains Buy on PepGen, Raises Price Target to $18 HC Wainwright & Co. analyst Ananda Ghosh maintains PepGen (NASDAQ:PEPG) with a Buy and raises the price target from $12 to $18.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com Wedbush Maintains Outperform on PepGen, Lowers Price Target to $8 Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $9 to $8.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
- benzinga.com Stifel Maintains Buy on PepGen, Raises Price Target to $12 Stifel analyst Paul Matteis maintains PepGen (NASDAQ: PEPG) with a Buy and raises the price target from $9 to $12.
benzinga.com S&P 500 Falls 1%; Accenture Posts Upbeat Earnings U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Thursday. The Dow traded down 0.64% to 45,824.16 while the NASDAQ fell 1.19% to 22,229.54. The S&P…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
benzinga.com Nasdaq Down Over 1%; US Initial Jobless Claims Fall U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 45,889.75 while the NASDAQ fell…
benzinga.com PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.- benzinga.com Wedbush Maintains Outperform on PepGen, Raises Price Target to $9 Wedbush analyst Laura Chico maintains PepGen (NASDAQ: PEPG) with a Outperform and raises the price target from $7 to $9.
benzinga.com CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.- benzinga.com HC Wainwright & Co. Maintains Buy on PepGen, Raises Price Target to $12 HC Wainwright & Co. analyst Ananda Ghosh maintains PepGen (NASDAQ: PEPG) with a Buy and raises the price target from $8 to $12.